CTI BioPharma Corp

-0.01 (-0.40%)
Regulatory, Earnings Announcements

CTI BioPharma Q1 Loss Per Share $0.23

Published: 06/01/2021 20:31 GMT
CTI BioPharma Corp (CTIC) - Cti Biopharma Reports First Quarter 2021 Financial Results.
Q1 Loss per Share $0.23.
Says NDA for Pacritinib for Treatment of Myelofibrosis Patients With Severe Thrombocytopenia Accepted With Priority Review by FDA.
Says Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in United States in 2021.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.